ACE and heart failure: In contrast to guidelines for management of heart failure patients in the general population, cardio-oncology guidelines [16–18] recommend LVETx with ACE inhibitors and β blockers for asymptomatic and mild LVD in the setting of cardiotoxic chemotherapy [17].